Newsroom | 40913 results

ROCKVILLE, Md.--(BUSINESS WIRE)--BIOQUAL, Inc. www.bioqual.com BIOQ(Pinksheets):     2025     2024   Revenue $ 48,867,753   $ 58,590,949   (Loss) Income Before Income Tax $ (1,896,010 ) $ 476,447   Net (Loss) Income $ (1,048,154 ) $ 483,481   Basic Earnings per Share of Common Stock $ (1.17 ) $ .54   Diluted Earnings per Share of Common Stock $ (1.17 ) $ .54   Weighted Average           Number of Shares Outstanding           For Basic Earnings Per Share   894,416     894,416   Weighted Average...

MINNEAPOLIS--(BUSINESS WIRE)--A study by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) found that a donor search prognosis-based strategy helps physicians move patients with blood cancers and other blood diseases to hematopoietic cell transplant (HCT) faster, resulting in similar transplant success regardless of likelihood of finding a matched unrelated donor (MUD). Investigators from the consortium of U.S. transplant centers, CIBMTR® (Center for International Blood and Marr...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Sobi® today announced that TRYNGOLZA® (olezarsen) has been approved in the European Union (EU) as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome (FCS). The approval follows the positive opinion of the Committee for Medicinal Products for Human Use. The approval is based on positive data from the Phase 3 Balance study, in which TRYNGOLZA 80 mg demon...

TORONTO--(BUSINESS WIRE)--Celltrion annonce aujourd'hui que Santé Canada a approuvé le Stoboclo™ et l'Osenvelt™ (CT-P41), des biosimilaires faisant référence au Prolia® et au Xgeva®, respectivement, pour toutes les indications de produits de référence.1,2 « L’approbation de Stoboclo et Osenvelt souligne notre engagement à développer des thérapies centrées sur le patient, en particulier pour les formes incurables de maladies telles que l’ostéoporose, où les patients sont confrontés à des pronost...

TORONTO--(BUSINESS WIRE)--Celltrion today announced that Health Canada has approved Stoboclo® and Osenvelt® (CT-P41), biosimilars referencing Prolia® and Xgeva®, respectively for all indications of reference products.1,2 “The approval of Stoboclo and Osenvelt underscores our commitment to developing patient-centric therapies, particularly for incurable forms of disease such as osteoporosis where patients face difficult prognoses,” said Jungyong Shin, Managing Director at Celltrion Healthcare Ca...

VANCOUVER, British Columbia--(BUSINESS WIRE)--Life Sciences BC 2025-26 Board of Directors Announcement...

DUBLIN--(BUSINESS WIRE)--The "Knowledge Process Outsourcing (KPO) Services Market - Delivery Models, Service Types, Company Types and Industry Sectors" report has been added to ResearchAndMarkets.com's offering. Valued at approximately US$63.7 billion in 2024, the market is projected to reach over US$157.5 billion by 2030, growing at a compound annual growth rate (CAGR) of 16.3%. This global report on Knowledge Process Outsourcing (KPO) Services market analyzes the global and regional market ba...

MONTVALE, N. J.--(BUSINESS WIRE)--Balchem, a global manufacturer of specialty ingredients for human nutrition, has launched its first direct-to-consumer initiative....

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). “Today is a turning point for eligible people in Italy living with transfusion-dependent beta thalassemia and sickle cell disease, two life-shortening diseases with...

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) today announced changes to its reportable segments and organizational structure, effective in the second quarter of fiscal year 2026. The new reporting structure enhances strategic alignment and transparency, supporting optimizing portfolio management to drive sustainable long-term value creation for shareholders. “McKesson has a long history of leadership in healthcare, continuously evolving to meet the needs of our customers, pr...